Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Inclusion Criteria:

Histologic diagnosis of classical, CD30 positive Hodgkin lymphoma confirmed at enrolling institution
FDG-avid disease by FDG-PET/CT and measurable disease of at least 1.5 cm by CT
Ann Arbor Stage I or II disease
Disease bulk defined as any lymph node mass with transverse maximal diameter > 7.0 cm OR coronal maximal diameter > 7.0 cm on CT imaging
Females of childbearing age must be on an acceptable form of birth control per institutional standards
Ages 18 and over

Exclusion Criteria:

Cardiac ejection fraction ≤ 50%
Hemoglobin-adjusted diffusing capacity for carbon monoxide < 40%
ANC≤1000/μl and Platelets≤75,000/μl
Total bilirubin ≥ 2.0 mg/dl in the absence of a history of Gilbert's disease
Serum creatinine clearance of <30 mL/min as estimated by the Cockcroft-Gault Method
Known pregnancy or breast-feeding
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
Medical illness unrelated to Hodgkin Lymphoma, which, in the opinion of the attending physician and/or MSKCC principal investigator, makes participation in this study inappropriate.
Peripheral neuropathy > grade 1
Patients receiving chronic treatment with systemic steroids. However, patients can receive up to 10 days of steroid therapy prior to starting treatment with BV+AVD.